Advertisement

Picture Berlin Partner BIO 2024 International Convention San Diego 650x100px
Organisation › Details

InflaRx N.V. (Nasdaq Global Select Market: IFRX)

InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a and C5aR technologies to discover and develop first-in-class or best-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. Complement C5a and its receptor C5aR are powerful inflammatory mediators involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. The COVID-19 related work for vilobelimab was partly funded by the German federal government through grant number 16LW0113 (VILO-COVID). All responsibility for the content of this work lies with InflaRx. *

 

Period Start 2017-06-01 established
  Group InflaRx (Group)
Products Industry anti-inflammatory drug
  Industry 2 IFX-1 (InflaRx)
Persons Person Riedemann, Niels C. (InflaRx 200803 Managing Director + founder)
  Person 2 Christ, Arnd (Immatics 202010– CFO before InflaRx + Proteros + MediGene + NovImmune + Probiodrug + Hoechst)
     
Region Region Amsterdam
  Country Netherlands
  City n. a. Amsterdam
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
  Currency EUR
  Profit -53,254,817 (2019-12-31)
  Cash 115,485,147 (2019-03-31)
     
    * Document for »About Section«: InflaRx N.V.. (12/21/22). "Press Release: InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19". Jena.
     
   
Record changed: 2024-02-23

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for InflaRx (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner BIO 2024 International Convention San Diego 650x300px




» top